The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia. Issue 9 (2nd September 2017)

• Record Type: Journal Article
• Authors: Tran, Phu N.; O'Brien, Susan
• Is Part Of: Expert opinion on drug safety. Volume 16:Issue 9(2017:Sep.)
• Page Start: 1079
• Page End: 1088
• Publication Date: 2017-09-02
• Subjects: BTK inhibitors -- chronic lymphocytic leukemia -- ibrutinib -- chemoimmunotherapy -- safety -- toxicity; Drugs -- Side effects -- Periodicals; Drugs -- Toxicology -- Periodicals; Chemotherapy -- Periodicals; 615.704
• DOI: 10.1080/14740338.2017.1344213
• Languages: English
• ISSNs: 1474-0338

Abstract

ABSTRACT: Introduction : The approval of ibrutinib has revolutionized the therapeutic landscape of chronic lymphocytic leukemia (CLL). Currently ibrutinib is indicated for patients that are both treatment naïve as well as those with relapsed CLL. Ibrutinib is generally well-tolerated with durable responses that improve over time in most patients. Important toxicities include atrial fibrillation and bleeding. Areas cover : This review covers the pharmacokinetics, pharmacodynamics, safety and efficacy of ibrutinib in the treatment of CLL. We also compare ibrutinib with other kinase inhibitors and chemoimmunotherapy regimens using data from clinical trials. A literature search utilized the PubMed database. Expert opinion : Despite the efficacy and tolerability of ibrutinib, important questions remain, which include selection of patients receiving ibrutinib in the first and subsequent lines of treatment, optimal dosing, sequential use of ibrutinib versus other kinase inhibitors and combination therapy. Prospective studies should incorporate minimal residual disease (MRD) status as a clinical endpoint to determine whether patients can be taken off kinase inhibitors.